CELICA BIOMEDICAL was established with a mission to pursue biomedical research and to efficiently transform findings into products and services that address significant challenges in biomedicine.
The key activities of CELICA BIOMEDICAL are the development of research technologies for the assessment of single-cell function, services related to confocal microscopy, scientific research in neuroglia, the development of technologies for the production of hybrid cells for use in cancer therapy through immunomodulation, and the development of new neurologic treatments based on targeting neuroglia.
Since 2000 CELICA BIOMEDICAL has been receiving funds from the Slovenian Research Agency and been actively engaged in the National Research Programme together with the Medical Faculty of the University of Ljubljana. CELICA BIOMEDICAL is a regular member of international projects such as those funded by the National Institute of Health (USA) and Framework Programme projects funded by the EU. CELICA BIOMEDICAL is a partner of Edu-GLIA, an Initial Training Network (ITN) funded by the European Commission under the Seventh Framework Programme (FP7).
CELICA BIOMEDICAL laboratories operate under a quality management system in compliance with the SIST EN ISO/IEC 17025:2005 standard.
The CELICA BIOMEDICAL research team collaborates closely with the Molecular Cell Physiology Lab at the University of Ljubljana, carrying out basic research projects aimed at understanding single-cell functioning and molecular events at subcellular organelle physiology level.
Techniques employed range from confocal microscopy, electrophysiology (capacitance measurements, Cambridge-NARIP® project), cytosolic calcium, cAMP, glucose, lactate measurements to molecular biology and others.
Since 2006, CELICA BIOMEDICAL has been operating a Carl Zeiss Reference Centre for Confocal Microscopy that is equipped with two LSM510 microscopes, one with a Faraday cage and the other with a Meta PMT array detector. Super-sensitive cameras are used in the Elyra platform for super-resolution microscopy. Image analysis is performed using the custom-made software packages Particle TR, Particle CO, ColocANA, CELL and others.
HybriCure® was developed with proprietary electrofusion technology that is designed to treat cancer. It consists of fused-tumour and antigen-presenting cells.
We have published a paper: Survival of castration-resistant prostate cancer patients treated with dendritic–tumor cell hybridomas is negatively correlated with changes in peripheral blood CD56brightCD16− natural killer cells in Clinical and Translational Medicine (CTM), Volume11, Issue8, https://doi.org/10.1002/ctm2.505For detailed information, please order a status report at:
development@celicabiomedical.com
The results of in-house research have established that SMART pharmacological agents (patented) robustly prevent pathological responses by neuroglia and are aimed at treating cognitive disorders, tissue response to trauma, Alzheimer's disease, multiple sclerosis and others.
For detailed information, please order a status report at:
development@celicabiomedical.com
CELICA BIOMEDICAL has, together with partners, developed innovative research technologies that have been used in basic research for more than 30 years. The performance and applicability of the instruments developed are guaranteed by certificates gained and numerous papers published in peer-reviewed journals.
Slovenian Research Agency, Carl Zeiss Reference Centre, Lek Pharmaceutical Company
(a member of the Sandoz Group)
National research programme
“Cell Physiology”
A list of peer-reviewed scientific
papers by the head the programme
“Cell physiology”.
Autologous hybridomas
(EudraCT # 2012-005498-29)
We are pleased to announce the publication of our paper titled: Survival of castration-resistant prostate cancer patients treated with dendritic–tumor cell hybridomas is negatively correlated with changes in peripheral blood CD56brightCD16− natural killer cells in Clinical and Translational Medicine (CTM), Volume 11, Issue 8; https://doi.org/10.1002/ctm2.505
We invite you to watch the video presentation: https://youtu.be/Cd7a6y98iY8
